InspireMDLogo.jpg
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
October 13, 2021 08:30 ET | InspireMD Inc.
TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery...
InspireMDLogo.jpg
InspireMD Announces Strong Second Quarter 2021 Financial Results
August 10, 2021 07:00 ET | InspireMD Inc.
Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET TEL AVIV, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc....
InspireMDLogo.jpg
InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update
August 04, 2021 08:30 ET | InspireMD Inc.
TEL AVIV, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
InspireMDLogo.jpg
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS
July 23, 2021 08:30 ET | InspireMD Inc.
TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
InspireMDLogo.jpg
InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
June 02, 2021 08:04 ET | InspireMD Inc.
TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery...
InspireMDLogo.jpg
InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq
May 27, 2021 08:00 ET | InspireMD Inc.
TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of...
InspireMDLogo.jpg
InspireMD Commences Trading on Nasdaq-CM
May 21, 2021 08:30 ET | InspireMD Inc.
TEL AVIV, Israel, May 21, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery...
NSPR Logo-3.jpg
InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021
May 14, 2021 06:00 ET | InspireMD Inc.
TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
NSPR Logo-3.jpg
InspireMD Announces Appointment of Katie Arnold to Board of Directors
May 12, 2021 06:00 ET | InspireMD Inc.
TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
NSPR Logo-3.jpg
InspireMD Announces First Quarter 2021 Financial Results
May 11, 2021 06:00 ET | InspireMD Inc.
Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021 Management to host investor conference call today, May 11, 2021, at 8:30am ET TEL AVIV, Israel,...